Argos Therapeutics is funded by a broad syndicate of top-tier life science
The Aurora Funds
Founded in 1994, The Aurora Funds is a venture capital firm that provides
capital, connections and strategic help to entrepreneurs with early-stage
life science and information technology companies, primarily in the Southeastern
and Mid-Atlantic United States. Aurora typically invests in seed and first-
round financing opportunities. The firm has more than $155 million of total
capital under management and is currently investing out of its fourth fund
of $85 million. The firm has the capacity to invest between $4 million
and $7 million throughout the life cycle of an investment.
FORBION CAPITAL PARTNERS
In 2007, Forbion Capital Partners (Forbion) spun out the life sciences
venture capital activities of ABN AMRO Capital to form a new, independent venture
capital group. Forbion raised a EUR 200 M fund with ABN AMRO and Coller Capital
as founding investors. The new fund incorporates the existing life sciences portfolio
of ABN AMRO Capital, valued at EUR 90 M.
GeneChem Therapeutics Venture Fund L.P. is fully dedicated to making investments
in companies concentrating their research and development efforts in the field
of proliferative disorders, e.g. cancer and infectious diseases. This is the
second GeneChem fund and it was launched in 2000 with a committed capital of
$137 million. It has invested in over 15 companies.
Intersouth is one of the nation’s most experienced early stage venture
capital firms, managing more than $500 million in six venture capital partnerships
since 1985. As one of the largest early stage firms in the Southeast and Mid-Atlantic
regions, it has invested in more than 75 companies, and focuses on the life sciences
and information technology sectors.
Built on a foundation that leverages 18 years of North American venture capital experience, the Lumira Capital team has been investing in transformational health and life science companies for more than a decade.
TVM Capital, founded in 1983, is one of the first
venture capital funds formed in Germany and a leader in transatlantic operations.
The German-U.S. venture capital company has offices in Munich and Boston.
For many years, TVM has focused on information technology and life sciences,
high growth sectors where innovation, effective management and sound financial
backing have enormous impact on company growth.
TVM funds have made investments
in over 220 technology companies in Europe and the United States. Many
of these enterprises went public on U.S. or European stock exchanges or
were sold to strategic acquirers.